HC Wainwright Reaffirms Buy Rating for Immunocore (NASDAQ:IMCR)

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $100.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 253.73% from the stock’s previous close.

Several other research firms have also weighed in on IMCR. Needham & Company LLC reissued a “buy” rating and issued a $71.00 target price on shares of Immunocore in a report on Thursday, February 27th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Price Performance

Shares of NASDAQ:IMCR opened at $28.27 on Wednesday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -29.76 and a beta of 0.79. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The business’s 50 day simple moving average is $30.10 and its 200-day simple moving average is $31.43. Immunocore has a 12 month low of $27.19 and a 12 month high of $66.00.

Hedge Funds Weigh In On Immunocore

Several large investors have recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore during the 4th quarter valued at about $25,000. China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares during the period. NEOS Investment Management LLC grew its stake in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares during the period. Tema Etfs LLC purchased a new position in shares of Immunocore in the 4th quarter worth $330,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after acquiring an additional 3,238 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.